Evox Therapeutics Limited

Active10076821 Private limited company

Incorporated: 22 March 2016 (10 years)
Industry: Research and experimental development on biotechnology (72110)
Directors: Oliver Mahony
Douglas Treco
Laura Ann Taylor Feinleib
all 7 directors
Owned by: Oxford Science Enterprises PLC
Accounts type: Full
Region: South East
Address: Medawar Centre 2nd Floor East Building
Robert Robinson Avenue
Oxford
OX4 4HG

Website & contact details

Group website: evoxtherapeutics.co.uk
The site of this company’s group or brand.

Filing status

Accounts due: 30 September 2027
Last accounts: 31 December 2025
Conf. stmt due: 30 March 2027
Last conf. stmt: 16 March 2026

Officers 7 active

Officer details are public data from the Companies House register.

Mahony, Oliver

Director · Appointed 9 July 2026

British

Born October 1983 (43)

Treco, Douglas

Director · Appointed 20 October 2025

American

Born August 1957 (69)

Feinleib, Laura Ann Taylor

Director · Appointed 13 March 2025

American

Born November 1995

Lundin, Per, Dr

Director · Appointed 26 April 2024

Swedish

Born April 1983 (43)

Caplan, Evan Samuel, Dr

Director · Appointed 13 April 2022

American

Born December 1988 (37)

Andrews, Martin

Director · Appointed 16 May 2020

British

Born July 1963 (63)

Gordon Wild, Sarah Lucinda

Director · Appointed 15 March 2017

Also at SGW Research Limited · more companies

British

Born May 1959 (67)

Officer history (12 former)

9 July 2026

Resigned Wallace, Wallace Lucy Elizabeth as Director

9 July 2026

Appointed Mahony, Oliver as Director

20 October 2025

Appointed Treco, Douglas as Director

12 September 2025

Appointed Wallace, Wallace Lucy Elizabeth as Director

9 September 2025

Resigned Hammacher, Alexander Eric as Director

13 March 2025

Appointed Feinleib, Laura Ann Taylor as Director

13 March 2025

Resigned Nagpal, Amrit as Director

26 April 2024

Appointed Lundin, Per, Dr as Director

26 April 2024

Resigned Rollet De Fougerolles, Antonin Robert, Dr as Director

26 April 2024

Resigned Carter, Paul Rutherford as Director

21 September 2023

Resigned Mchutchison, John George as Director

21 September 2023

Appointed Hammacher, Alexander Eric as Director

13 April 2022

Appointed Caplan, Evan Samuel, Dr as Director

1 March 2022

Resigned Khuong, Chau Q. as Director

16 February 2021

Resigned Lundin, Per, Dr as Director

16 February 2021

Resigned Wood, Matthew John Andrew, Prof as Director

16 February 2021

Appointed Khuong, Chau Q. as Director

6 January 2021

Appointed Mchutchison, John George as Director

30 June 2020

Resigned Mclean, Andrew James, Dr as Director

16 May 2020

Appointed Andrews, Martin as Director

17 April 2020

Appointed Carter, Paul Rutherford as Director

23 March 2020

Resigned Moses, Edwin, Dr as Director

8 February 2019

Appointed Nagpal, Amrit as Director

8 February 2019

Appointed Moses, Edwin, Dr as Director

5 February 2019

Resigned Stoten, Adam, Dr as Director

17 October 2017

Appointed Rollet De Fougerolles, Antonin Robert, Dr as Director

15 March 2017

Appointed Gordon Wild, Sarah Lucinda as Director

7 April 2016

Appointed Lundin, Per, Dr as Director

7 April 2016

Appointed Wood, Matthew John Andrew, Prof as Director

7 April 2016

Appointed Stoten, Adam, Dr as Director

22 March 2016

Appointed Mclean, Andrew James, Dr as Director

Ownership 1 active

People and entities with significant control, from the Companies House PSC register

Oxford Science Enterprises PLC

Corporate entity · Notified 6 April 2016

Owns 25–50% of shares

Holds 25–50% of voting rights

Public Limited Company

Reg. no. 09093331

Group structure 17 shown

Ownership group derived from the Companies House PSC register

Oxford Science Enterprises PLC

Acionna Therapeutics Ltd Owns 50–75% of shares

Animal Dynamics Limited Owns 50–75% of shares

Archangel Lightworks Ltd Owns 25–50% of shares

Ascension Earth Resources Ltd Owns 25–50% of shares

Caudal Energy Limited Owns 25–50% of shares

Caudal Morlais Limited Owns 75–100% of shares

Circadian Therapeutics Limited Owns 75–100% of shares

Cora Biosciences Limited Owns 25–50% of shares

Credo Therapies Ltd Owns 50–75% of shares

Dark Horse Technologies Ltd In liquidationOwns 25–50% of shares

Densix Limited Owns 25–50% of shares

Dyna Therapeutics Limited Owns 50–75% of shares

Eligentis Limited Owns 25–50% of shares

Enzbond Limited DissolvedOwns 50–75% of shares

Evox Therapeutics Limited This company Owns 25–50% of shares

Fluorok Limited Owns 25–50% of shares

And 32 more

Filings 100

Date	Description	Made Up To
18 September 2026	Statement of capital following an allotment of shares
4 September 2026	Statement of capital following an allotment of shares
11 August 2026	Appointment of a director
10 August 2026	Termination of appointment of a director
18 April 2026	Full accounts	31 December 2025